Article
TS gene polymorphisms are not good markers of response to 5-FU therapy in stage III colon cancer patients.
Cellular oncology (Dordrecht, Netherlands) - 1 Aug 2011
Fariña-Sarasqueta A, Gosens M J E M, Moerland E, van Lijnschoten I, Lemmens V E P P, Slooter G D, Rutten H J T, van den Brule Adriaan J C
Abstract excerpt
AIM: Although the predictive and prognostic value of thymidylate synthase (TS) expression and gene polymorphism in colon cancer has been widely studied, the results are inconclusive probably because of methodological differences. With this study, we aimed to elucidate the role of TS gene polymorphisms genotyping in therapy response in stage III colon carcinoma patients treated with 5-FU adjuvant chemotherapy....
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.
